Video
Promising Alzheimer Antibody-Based Immunotherapy
Author(s):
Dr. Bobby Lazzara reports on a clinical trial of aducanumab, a human monoclonal antibody, in patients with prodromal or mild Alzheimer disease.
Aducanumab, a human monoclonal antibody, selectively targets aggregated amyloid-β. In this Medical News Minute, developed exclusively for Neurology Times, Dr. Bobby Lazzara discusses a one-year study of monthly intravenous infusions of aducanumab that has shown a slowing of clinical decline measurements in Alzheimer disease. A phase III trial of the drug is ongoing.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Videos
Related Content
